摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2S,3R)-3-(叔丁氧羰基氨基)-1,2-环氧-4-苯基丁烷 | 156474-22-5

中文名称
(2S,3R)-3-(叔丁氧羰基氨基)-1,2-环氧-4-苯基丁烷
中文别名
——
英文名称
tert-butyl [(2R,3S)]-(-)-(1-oxiranyl-2-phenylethyl)carbamate
英文别名
tert-butyl ((R)-1-((S)-oxiran-2-yl)-2-phenylethyl)carbamate;(2S,3R)-3-tert-butoxycarbonylamino-1,2-epoxy-4-phenylbutane;(2S)-[1'(R)-Boc-amino-2'-phenylethyl]oxirane;tert-butyl N-[(1R)-1-[(2S)-oxiran-2-yl]-2-phenylethyl]carbamate
(2S,3R)-3-(叔丁氧羰基氨基)-1,2-环氧-4-苯基丁烷化学式
CAS
156474-22-5
化学式
C15H21NO3
mdl
——
分子量
263.337
InChiKey
NVPOUMXZERMIJK-CHWSQXEVSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    90-95°C
  • 沸点:
    398.8±25.0 °C(Predicted)
  • 密度:
    1.118±0.06 g/cm3(Predicted)
  • 溶解度:
    可溶于氯仿、DMSO、甲醇

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    19
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.53
  • 拓扑面积:
    50.9
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    存储条件:2-8°C,干燥密封。

SDS

SDS:768c0de426b91e65cf8ca09080fcf7a7
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (2S,3R)-3-(叔丁氧羰基氨基)-1,2-环氧-4-苯基丁烷 在 lithium hydroxide 作用下, 以 1,4-二氧六环二氯甲烷异丙醇 为溶剂, 反应 20.0h, 生成
    参考文献:
    名称:
    Stereochemical Analysis of (Hydroxyethyl)urea Peptidomimetic Inhibitors of γ-Secretase
    摘要:
    (Hydroxyethyl)urea peptidomimetics systematically altered at positions P2-P3' with hydrophobic D-amino acids were synthesized. An all D-amino acid containing analogue was identified that effectively blocked gamma-secretase activity in a cell-free system (IC50 = 30 nM). Systematic alteration of the stereocenters of a potent compound revealed interdependence between the various positions. Although typically less potent than their L-peptidomimetic counterparts. selected all D-amino acid containing analogues were equipotent. to their counterparts in a cell-based assay when incubated for extended times.
    DOI:
    10.1021/jm049566e
  • 作为产物:
    参考文献:
    名称:
    Stereochemical Analysis of (Hydroxyethyl)urea Peptidomimetic Inhibitors of γ-Secretase
    摘要:
    (Hydroxyethyl)urea peptidomimetics systematically altered at positions P2-P3' with hydrophobic D-amino acids were synthesized. An all D-amino acid containing analogue was identified that effectively blocked gamma-secretase activity in a cell-free system (IC50 = 30 nM). Systematic alteration of the stereocenters of a potent compound revealed interdependence between the various positions. Although typically less potent than their L-peptidomimetic counterparts. selected all D-amino acid containing analogues were equipotent. to their counterparts in a cell-based assay when incubated for extended times.
    DOI:
    10.1021/jm049566e
点击查看最新优质反应信息

文献信息

  • Catalytic Formation of Cyclic Carbonates using Gallium Aminotrisphenolate Compounds and Comparison to their Aluminium Congeners: A Combined Experimental and Computational Study
    作者:Lucía Álvarez‐Miguel、Jesús Damián Burgoa、Marta E. G. Mosquera、Alex Hamilton、Christopher J. Whiteoak
    DOI:10.1002/cctc.202100910
    日期:2021.10.7
    of gallium aminotrisphenolate compounds as catalysts for the synthesis of cyclic carbonates from epoxides and CO2. The results show that they are highly active, and more so than the corresponding aluminium congeners. The catalyst system is applicable at low and elevated temperatures across a wide substrate scope including terminal, internal, multiple and fully deuterated epoxides. Applying low catalyst
    这项工作报告了使用基三化合物作为由环氧化物和 CO 2合成环状碳酸酯的催化剂. 结果表明它们具有高活性,并且比相应的铝同系物活性更高。该催化剂体系适用于低温和高温下的广泛底物范围,包括末端环氧化物、内部环氧化物、多重环氧化物和完全环氧化物。应用低催化剂负载量可以获得 344,000 的 TON,突出了它们的稳定性。DFT 研究证实,与铝同系物相比,催化剂具有较低的能量分布。使用 Gutmann-Beckett 方法测量基三铝化合物的路易斯酸度提供了实验证据,证明化合物比其铝同系物更具路易斯酸性。最后,
  • Diastereoselective epoxidation of allylically substituted alkenes using metalloporphyrin catalysts
    申请人:Che Chi-Ming
    公开号:US20050209470A1
    公开(公告)日:2005-09-22
    Diastereoselective epoxidation of allylically substituted alkenes using metalloporphyrins as catalyst provides high trans-selectivities (i.e., trans-:cis-epoxide ratio). A diversity of cycloalkenes bearing different allylic substituents are shown to be efficiently epoxidized to afford the corresponding trans-epoxides with excellent trans-selectivities (up to >98%) and good yields (up to 99%). Acyclic allylic alkenes bearing different allylic substituents are efficiently epoxidized to afford the corresponding erythro-epoxides with good erythro-selectivities. The metalloporphyrin-catalyzed reactions exhibit up to 20 times higher trans-selectivities than the conventional method using m-chloroperoxybenzoic acid as oxidant.
    使用卟啉作为催化剂的烯丙基取代烯烃的非对映选择性环氧化反应提供高选择性(即反式:顺式环氧化物比)。显示出带有不同烯丙基取代基的多样环烯烃能够有效地环氧化,产生相应的反式环氧化物,具有优异的反式选择性(高达>98%)和良好的产率(高达99%)。带有不同烯丙基取代基的无环烯丙基烯烃能够有效地环氧化,产生相应的顺式环氧化物,具有良好的顺式选择性。卟啉催化的反应显示出比使用m-过氧苯甲酸作为氧化剂的传统方法高达20倍的反式选择性。
  • PROCESS FOR PREPARATION OF DARUNAVIR
    申请人:Laurus Labs Private Limited
    公开号:US20150203506A1
    公开(公告)日:2015-07-23
    Provided are a process for preparation of darunavir or solvates or a pharmaceutically acceptable salt thereof substantially free of bisfuranyl impurities and a process for preparation of amorphous darunavir using the darunavir propionate solvate.
    提供了一种制备几乎不含双呋喃基杂质的达芦那韦或其溶剂合物或药用可接受的盐的过程,以及利用达芦那韦丙酸盐溶剂合物制备非晶态达芦那韦的过程。
  • Pharmacokinetics of protease inhibitors and other drugs
    申请人:Mutz Mitchell W.
    公开号:US20080306098A1
    公开(公告)日:2008-12-11
    A method for modulating at least one pharmacokinetic property of a protease inhibitor upon administration to a host is provided. One administers to the host an effective amount of a bifunctional compound of less than about 5000 daltons comprising the protease inhibitor or an active derivative thereof and a pharmacokinetic modulating moiety. The pharmacokinetic modulating moiety binds to at least one intracellular protein. The bifunctional compound has at least one modulated pharmacokinetic property upon administration to the host as compared to a free drug control that comprises the protease inhibitor.
    提供了一种在给宿主施用蛋白酶抑制剂时调节至少一种药代动力学特性的方法。向宿主施用不超过约5000道尔顿的双功能化合物的有效量,该化合物包括蛋白酶抑制剂或其活性衍生物和药代动力学调节基团。药代动力学调节基团结合至少一个细胞内蛋白质。与包含蛋白酶抑制剂的自由药物对照相比,双功能化合物在向宿主施用后具有至少一个调节的药代动力学特性。
  • Antipicornaviral compounds, compositions containing them, and methods for their use
    申请人:——
    公开号:US20040072907A1
    公开(公告)日:2004-04-15
    A magnetic circuit component having a plurality of claws arranged in a plurality of rows, with the base of each claw connected to a common yoke. A plurality of non-interlaced coils constituting a multi-phase winding are included, with the coils being wound around the bases of corresponding claws, and being distributed uniformly in the direction of motion.
    一种磁路元件,其具有多个爪子,这些爪子排列成多行,每个爪子的底部连接到一个共同的轭上。包括多个非交错线圈的多相绕组,这些线圈绕在相应爪子的底部上,并在运动方向上均匀分布。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫